window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Therapeutic Areas

  • Clinical & Regulatory,Medical devices,Pharmaceuticals and therapeutics,Therapeutic Areas

    FDA grants De Novo authorisation to Avulux migraine light-sensitivity lens

    The FDA has granted De Novo marketing authorisation to Avulux, [...]

    August 24, 2026
  • Clinical & Regulatory,Digital & Data,Medical devices,Research & Development,Therapeutic Areas

    Oxford research to explore AI stroke prediction from routine cardiac CT at ESC 2026

    University of Oxford-led research will examine whether artificial intelligence can [...]

    August 24, 2026
  • Clinical & Regulatory,Medical devices,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Robotic gastrectomy shows benefits over laparoscopic surgery in gastric cancer

    Large Japanese study finds robotic surgery reduces blood loss, conversions [...]

    August 24, 2026
  • Central Nervous System,Clinical & Regulatory,Digital & Data,Pharmaceuticals and therapeutics,Therapeutic Areas

    Limbic selected for FDA pilot to test AI-led mental healthcare

    Limbic has been selected for the US Food and Drug [...]

    August 19, 2026
  • Advanced Therapies,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    Andelyn and Queen’s University partner on AAV9 gene therapy for GM2 gangliosidoses

    Andelyn Biosciences and Queen’s University have partnered to develop and [...]

    August 19, 2026
  • Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Pusan National University study links stress signalling to immune escape in cold tumours

    A Pusan National University study has identified a signalling pathway [...]

    August 19, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Hansa Biopharma treats first commercial kidney transplant patient with Idefirix in Australia

    Hansa Biopharma has treated the first commercial Australian living donor [...]

    August 19, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE recommends glycopyrronium cream for severe underarm sweating

    NICE has recommended glycopyrronium bromide cream as an option for [...]

    August 17, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE recommends allergy immunotherapy tablets for children with hay fever and house dust mite allergy

    NICE has recommended sublingual immunotherapy tablets for children with moderate [...]

    August 17, 2026
  • Digital & Data,Pharmaceuticals and therapeutics,Therapeutic Areas

    Tris Pharma partners with Calm Health and ADHD Central to support patients

    Tris Pharma has announced partnerships with Calm Health and ADHD [...]

    August 14, 2026
Previous345Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Resolution Therapeutics completes Phase 1/2 RTX001 liver disease trial dosing
    Categories: Advanced Therapies, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Eleva separates biologics platform from Factor H therapy
    Categories: Advanced Therapies, Biotech & Pharma Business, Pharmaceuticals and therapeutics, Research & Development
  • ENA Respiratory begins Phase 2a dosing of nasal antiviral INNA-051
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top